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Abstract
Objective
The SCN1A gene, coding for the voltage-gated Na+ channel alpha subunit NaV1.1, is the
clinically most relevant epilepsy gene. With the advent of high-throughput next-generation
sequencing, clinical laboratories are generating an ever-increasing catalogue of SCN1A
variants. Variants are more likely to be classified as pathogenic if they have already been
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identified previously in a patient with epilepsy. Here, we critically re-evaluate the pathoge-
nicity of this class of variants in a cohort of patients with common epilepsy syndromes and
subsequently ask whether a significant fraction of benign variants have been misclassified
as pathogenic.
Methods
We screened a discovery cohort of 448 patients with a broad range of common genetic epi-
lepsies and 734 controls for previously reported SCN1Amutations that were assumed to be
disease causing. We re-evaluated the evidence for pathogenicity of the identified variants
using in silico predictions, segregation, original reports, available functional data and
assessment of allele frequencies in healthy individuals as well as in a follow up cohort of
777 patients.
Results and Interpretation
We identified 8 known missense mutations, previously reported as pathogenic, in a total of
17 unrelated epilepsy patients (17/448; 3.80%). Our re-evaluation indicates that 7 out of
these 8 variants (p.R27T; p.R28C; p.R542Q; p.R604H; p.T1250M; p.E1308D; p.R1928G;
NP_001159435.1) are not pathogenic. Only the p.T1174S mutation may be considered as
a genetic risk factor for epilepsy of small effect size based on the enrichment in patients (P =
6.60 x 10−4; OR = 0.32, fishers exact test), previous functional studies but incomplete pene-
trance. Thus, incorporation of previous studies in genetic counseling of SCN1A sequencing
results is challenging and may produce incorrect conclusions.
Introduction
The SCN1A gene (MIM#182389), coding for the voltage-gated Na+ channel alpha subunit
NaV1.1, is the most clinically relevant epilepsy gene. SCN1A variants are associated, at the
more benign end of the disease spectrum, with the dominantly inherited genetic epilepsy with
febrile seizures plus [1, 2] (GEFS+), and, at the severe end, with Dravet syndrome (DS), an epi-
leptic encephalopathy arising from de novo SCN1Amutations in the vast majority of DS
patients [3]. More rarely, SCN1Amutations are also found in other types of infantile epileptic
encephalopathies [4]. Common variants in SCN1A have been associated with mesial temporal
lobe epilepsy and hippocampal sclerosis with febrile seizures in a genome-wide association
study [5], and in a recent meta-analysis including 8696 patients with genetic generalized-,
focal-, or unclassified epilepsies [6]. In around 88% of epilepsy patients carrying rare SCN1A
mutations, these arise de novo, whereas only 12% of the affected individuals inherit the muta-
tion from a, usually unaffected, parent [4]. Patients with an identical mutation may express a
broad spectrum of phenotypes even within a single large family ranging from unaffected, over
GEFS+ to Dravet syndrome [7, 8]. Most functional studies of disease-associated variants
showed loss-of-function effects of SCN1Amutations [9–12]. Mutations with a complete loss of
function, in general, lead to more severe epilepsies [3, 13, 14].
Massive parallel sequencing studies have accelerated mutation discovery. With declining
costs, more patients will be sequenced, and many newly identified mutations are expected.
Determination of the functional consequences and pathogenicity is challenging and molecular
studies for each variant are currently not feasible. Databases like the "The Human Gene
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Mutation Database" (HGMD; http://www.hgmd.org/) constitute a comprehensive collection of
mutations in genes underlying or associated with human inherited diseases. The database is
routinely accessed and utilized by next generation sequencing (NGS) project researchers,
human molecular geneticists, neurologists and genetic counselors.
Interpretation of genetic results is challenging, especially in multifactorial diseases like com-
mon epilepsies. The HGMD comprises more than 1000 disease-associated mutations anno-
tated for the SCN1A gene (accessed Dec/2014). Here, we investigated a already whole-exome
sequenced cohort of 448 patients with a broad range of common genetic epilepsies, for SCN1A
mutations listed as disease associated in the HGMD. We re-evaluated the identified variants’
evidence for pathogenicity by in silico prediction, segregation, literature review for clinical,
genetic and functional relevance and assessment of allele frequencies in healthy individuals.
Finally, we investigated the phenotypic spectrum of the most reliable variant in a diagnostic
epilepsy cohort.
Patients and Methods
Patients and sequencing
Patients of European and Turkish ancestry were recruited at several centers from Germany,
Austria, Italy, Finland, Canada and Turkey. We included Turkish patients since SCN1A variant
frequencies do not show correlation with the ethnicity when compared between Asian and
European patients [4]. Samples from The Rotterdam Study [15] not specifically screened for
European ethnicity, which were handled in the same way as our cases, i.e. using the same
enrichment and sequencing methods, served as controls for the whole exome dataset. The con-
trols are drawn from the population and are not evaluated for seizure disorders. Informed con-
sent for whole exome sequencing was obtained from all participants or legal representatives
respectively. The two institutions in charge of the reported analysis are the University hospitals
in Tübingen (for “genetic generalized epilepsy”) and Giessen (for “genetic focal epilepsy”), Ger-
many. Both review boards in Tübingen and Giessen approved this study.
High-throughput, targeted sequencing was performed as previously described [16] with the
Nimblegen-SeqCapEZ-V244M enrichment kit on the Illumina HiSeq2000 system. For each
sample, we calculated the gene-coverage of SCN1A. Only samples with a minimum of 90% of
all bases in the coding region of the gene (i.e. all exons plus the first and last five intronic bases,
NM_001165963.1) being covered by at least 15 reads were used. After quality control, 448
unrelated epilepsy patients (235 with genetic generalized epilepsy; 182 with rolandic epilepsy;
22 with atypical rolandic epilepsy; 4 with benign familial neonatal seizures; 4 with benign
familial infantile epilepsy; 1 with benign adult familial myoclonic epilepsy; 226 males, 222
females) and 734 control individuals (435 females, 299 males) were included in the analysis.
All SCN1AHGMD variants identified in the patients were validated with Sanger sequencing
using standard protocols. Primers are available upon request. Rare SCN1A sequence variants,
which are not annotated by HGMD, were not investigated in this study.
HGMD annotation and assessment of the literature
Variant annotation was performed using the HGMD Professional 2013.4–15th December 2013
Version [17]. We assessed original reports cited by the HGMD for each identified HGMD
patient mutation. We re-analyzed the mutations, and if the original report used the sequence
of a shorter transcript of the SCN1A gene for numbering we numbered the variant accordingly
to the RefSeqGene (NM_001165963.1; which represent the longest transcript and reference
protein NP_001159435.1) used in our data set.
Re-Evaluation of SCN1A Epilepsy Variants
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Assessment of mutation frequency in controls
Besides our control dataset, variant frequencies were taken from the ExAC collection (http://
exac.broadinstitute.org/). Note that this database also includes patients from the "Swedish
Schizophrenia & Bipolar Studies”. Furthermore, it is not clear if patients with mild seizure dis-
orders have been excluded.
In silico prediction
Functional prediction scores were obtained from the dbNSFP database version 2.8 (http://sites.
google.com/site/jpopgen/dbNSFP, accessed 01/2015). In total we used six prediction scores
(SIFT, Polyphen-2-HVAR, Polyphen-2-HDIV, Mutation Assessor, FATHMM, LRT) and two
conservation scores (GERP++, PhyloP). We did not use the dbNSFP generated ensemble
scores, as they integrate the prediction of the tool Mutation Taster, which itself incorporates
HMGD entries. We classified the variant as “damaging” when the majority of the tools pre-
dicted a functional effect for the variant (i.e. a minimum of 5 out of 8 tools). Topology and
domain structure were taken from UniProt entry P35498.
Screening of the p.T1174S mutation in a diagnostic cohort of epilepsy
To further investigate the frequency and phenotypic spectrum of the p.T1174S mutation, we
evaluated NGS panel sequencing data of epilepsy-associated genes [18] of 777 individuals pro-
vided by the CeGaT diagnostic lab (http://www.cegat.de, genes listed in S1 Table). Patients cov-
ered a broad spectrum of epilepsy phenotypes, often associated with intellectual disability.
Criteria for variant re-classification
We consider a variant as pathogenic if all of the following three criteria are met: i) The variant
is statistically enriched in the patient cohort and/or absent in controls; ii) the segregation pat-
tern analysis and the re-evaluation of original reports do not weaken the epilepsy association,
iii) the variant is predicted to be pathogenic by the majority of in silico classifiers and/or molec-
ular functional analyses supports its pathogenicity.
Results
Case vs. control HGMD analysis
We analyzed sequence data of 448 epilepsy patients and 734 controls for SCN1A variants previ-
ously reported as disease causing collected by the HGMD. Our mutation screening identified
eight distinct HGMDmissense mutations (Table 1: p.R27T, p.R28C, p.R604H, p.R542Q, p.
T1174S, p.T1250M, p.E1308D, p.R1928G) affecting in total 17 unrelated epilepsy patients (17/
448 = 3.80%) compared to six HGMD variants affecting 10 control individuals (10/
734 = 1.36%). None of these patients were carrier of a rare loss of function variant in a known
epilepsy gene (S2 Table). The SCN1AHGMD variant frequency was therefore slightly enriched
in the patient cohort (P = 8.30 x 10−3). A high allele frequency in public databases would argue
against pathogenicity of the identified SCN1AHGMD variants identified in our patients. In
addition to our own sequenced controls we investigated the SCN1AHGMD variant frequencies
further using the ExAc, a publicly accessible variant database of 60706 unrelated individuals.
All eight variants were found in individuals collected in the ExAc database (Table 1). After
combining our in-house control and ExAc data in a meta-analysis, only the p.T1174S variant
remained significantly enriched after correction for multiple testing (Table 1) in epilepsy
patients supporting p.T1174S as the only identified SCN1A genetic risk factor for epilepsy in
our cohort.
Re-Evaluation of SCN1A Epilepsy Variants
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Segregation analysis
We further analyzed the family segregation pattern whereby a shared segregation of the SCN1A
HGMD variant and epilepsy was evaluated as support for the variant pathogenicity. For five vari-
ants detected in patients (p.T1250M, p.T1174S, p.R604H, p.R542Q, p.R28C), segregation analysis
was possible in a total of nine families (Fig 1). All variants were inherited, five times maternally
and three times paternally, six times from a healthy parent and only twice from an affected par-
ent. Only the p.T1174S variant segregated with epilepsy in our investigated families (Fig 1).
Review of the original reports
Next, we went back to the 16 original reports (1–4 cited reports for each mutation, Table 2) of
all eight identified patient mutations referenced in the HGMD to summarize inheritance, seg-
regation and available functional data. The majority of the reports do not support the disease
association of the variant from a today’s perspective. None of the mutations have been
described as de novo. In three reports (p.R604H, p.E1308D, p.R1982G) an additional SCN1A
mutation has been reported in the HGMD referenced patient, including a stop codon mutation
(p.R604H in combination with p.R1525X; p.R1928G in combination with p.L1207P, and p.
E1308D in combination with p.A239V; Table 2). In another study the HGMD referred patient
had two additional SCN1Amutations, one missense and one splice site acceptor variant
(Table 2, p.T1250M in combination with p.R27T and c.3706-2A>G). In four families the
mutation was inherited (each one family: p.R27T, p.R542Q, p.T1174S, p.E1308D; Table 2)
from a healthy parent and segregation was not determined in 12 families. In contrast, only in
three families the mutation segregated with the disease, one affected by the p.R604H and two
by the p.T1174S variants. Furthermore, only for the p.T1174S variant functional studies have
been conducted. In particular, experiments in tsA-201 cells and computational modeling of
mutant properties both supported its epileptogenic effect [19].
In silico prediction analysis
Six of the eight identified variants (p.R28C, p.R542Q, p.R604H, p.T1250M, p.E1308D and p.
R1928G) are predicted to have a damaging effect when both structural prediction and local
conservation scores were considered (Table 3). In contrast to previous molecular studies [19]
Table 1. HGMD SCN1Amutation frequencies in patients and controls.
Mutation dbSNP ID Patient mutation carrier in
(N = 448)
Controls
(N = 734)
Patient vs.
Controls
ExAC
(N = 60706)
Patient vs. controls
+ ExAC
p.
R1928G
rs121917956 1 0 - 171/60605 1
p.E1308D rs121917910 1 2 - 91/60276 0.498
p.T1250M rs140731963 1 0 - 42/58362 0.277
p.T1174S rs121918799 6 0 3.02 x 10−3 214/60675 5.61 x 10−3
p.R604H rs121918769 5 1 7.91 x 10−3 185/60690 0.013
p.R542Q rs121918817 1 5 - 186/60687 1
p.R28C No ID 1 0 - 4/60701 0.036
p.R27T rs121917906 1 0 - 14/60702 0.103
Accession according to reference transcript NM_001165963.1; and references protein NP_001159435.1; P values ware calculated either by Fisher’s exact
test; bold P values are still signiﬁcant after Bonferroni correction = α/n. For testing eight mutations with a desired α = 0.05, the Bonferroni correction tests
each individual hypothesis at α = 0.05/8 = 0.00625
doi:10.1371/journal.pone.0150426.t001
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and our statistical enrichment and segregation studies, the p.T1174S variant was not predicted
to be damaging by the majority of prediction tools (Table 3).
Replication analysis p.T1174S
Overall, after the initial re-evaluation of the identified SCN1AHGMD variants, we suggest that
only the p.T1174S variant is potentially a epilepsy associated variant. The p.T1174S variant is
enriched in patients, segregates with the phenotype in families and published functional data
support pathogenicity of the variant (Table 2). A major factor in our variant classification is
comparing the allele frequency differences between patients and controls. To further assess the
frequency of p.T1174S alleles in epilepsy patients and replicate our association, we investigated
an additional epilepsy cohort provided by the CeGaT diagnostic lab using targeted sequencing.
We identified seven out of 777 epilepsy patients (0.90%) carrying the p.T1174S SCN1Amuta-
tion. Four of the patients were diagnosed with intellectual disability and epilepsy, one patient
had temporal lobe epilepsy, and two patients had epileptic seizures without further specifica-
tion of the phenotype. In five of the seven patients, the mutation had been inherited from a
healthy parent. In the remaining two cases, parents were not available for segregation testing.
Of note, in one of the seven patients, an additional pathogenic variant was detected by detec-
tion of a de novomutation in GRIN2B [34] (c.1619G>A, p.R540H).
Combining both epilepsy cohorts together, we have identified 13 out of 1219 patients carry-
ing the p.T1174S mutation. A comparison of all available patient and control data confirms
Fig 1. Segregation analysis of the identified variants. Analysis of likely segregation of the respective
mutations in family members could be performed in eleven families. Accession is according to reference
transcript NM_001165963.1; and references protein NP_001159435.1. Abbreviations: FC = febrile
convulsion; JME = juvenile myoclonic epilepsy, CAE: childhood absence epilepsy, JAE: juvenile absence
epilepsy, EGMA: epilepsy with generalized tonic-clonic seizures predominantly on awakening, EOAE = Early
onset absence epilepsy, RE = Rolandic epilepsy, Abs = absence, BFNE = Benign familial neonatal seizure,
FSW = Focal SharpWaves, GTCS = Generalized tonic-clonic seizure
doi:10.1371/journal.pone.0150426.g001
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enrichment in epilepsy patients (P = 5.68 x 10−4; OR = 3.08, 95%-CI: 1.61–5.40, fisher exact
test, 13/1219 patients vs. 21461409 controls).
Discussion
In the context of molecular genetic testing, it is often challenging to establish the pathogenicity
of an intragenic variant. Lack of parental DNA or control individuals, absence of functional
data and association with different phenotypes add to this complexity.
Table 2. Summary of previous studies referenced at the HGMD specific for each identified variant.
Mutation Previous
Phenotype
Previous inheritance Comment Ref Phenotypes in
this study
p.
R1928G
GEFS+ Not determined - [1] 1x CAE
Control Not determined - [1]
SMEI Not determined Patient carried an additional p.L1207P mutation in
SCN1A
[20]
p.
E1308D
FC Not determined - [21] 1x JAE
SMEI Inherited from healthy father Patient carried an additional m p.A239V mutation in
SCN1A
[22]
p.
T1250M
DS Not determined Patient has an additional SCN1A missense mutation
(p.Arg27Thr) and one variant predicted as splice Site
acceptor mutation (c.3706-2A >G)
[23] 1x RE
GEFS+ - [21]
p.
T1174S
DS + Migraine Maternal inherited Patient has DS, mother has migraine with aura [24] 1x GTCS, 2x
RE, 1x
SMEI Not determined - [25] BFNE, 1x CAE,
1x JAE
Seizures and
hemiplegic
migraine
Large family: all mutation carriers had
epilepsy or migraine. 3x migraine with
aura, 1 migraine without aura and benign
occipital epilepsy, 2x migraine with aura
and benign occipital epilepsy = >
inherited
Functional studies, interpretation = modulation of the
properties of T1174S can lead to a switch between
overall gain and loss of function, consistent with a
switch between promigraine end epileptogenic effect
and, thus, with coexistence of epileptic and FHM
phenotypes in the same family.
[19]
MAE Inherited from healthy mother - [26]
FHM Not determined - [27]
p.R604H Intractable
Epilepsy
Not determined [28] 2x JME;
FS, FS+ Inherited all affected With a single family, All three mutation carrier had FS
or FS+
[29] 1x CAE, 1xRE,
1x EOAE
DS Not determined Patient carries also a SCN1A Stop codon mutation
(p.R1525X)
[30]
p.R542Q JME Not determined - [31] 1x RE
Familial autism Inherited from healthy father A sib with autism is affected and carries the mutation
as well
[32]
ICE Not determined - [28]
p.R28C GEFS+ Not determined - [33] 1x JAE
p.R27T GEFS+ Inherited from healthy father - [22] 1x JME
Abbreviations: GEFS+ = genetic epilepsy with febrile seizures plus; SMEI = severe myoclonic epilepsy of infancy; FC = febrile convulsion; DS = Dravet
Syndrome; MAE = Myoclonic astatic epilepsy (Doose syndrome); FHM = Familial hemiplegic migraine; FS = febrile seizures; JME = juvenile myoclonic
epilepsy, ICE = Intracable childhood epilepsy; GGE syndromes: CAE: childhood absence epilepsy, JAE: juvenile absence epilepsy, JME: juvenile
myoclonic epilepsy, EGMA: epilepsy with generalized tonic-clonic seizures predominantly on awakening, EGTCS: epilepsy with generalized tonic-clonic
seizure
doi:10.1371/journal.pone.0150426.t002
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In this study, we investigated the liability of SCN1A variants that were previously classified
as pathogenic, in a cohort of common epilepsy syndromes. We detected an enrichment of
HGMD annotated variants in our epilepsy patient cohort compared to controls (P = 8.30 x
10−3). All identified HGMD SCN1A variants in our patients have also been detected in control
individuals arguing against completely penetrant causal mutations. None of the variants were
localized in the transmembrane regions of the protein (S1 Fig), where mutations are associated
with more severe channel dysfunctions [13]. We considered seven, out of the eight (p.R27T, p.
R28C, p.R542Q, p.R604H p.T1250M, p.E1308D, p.R1928G) analyzed HGMD variants, as obvi-
ous benign based on the original reports, the high frequency in control individuals and missing
or negative segregation and functional results (Tables 1 and 2; Fig 1).
In contrast to the other mutations classification of the p.T1174S mutation is less trivial. On
the one hand, support as a potential genetic risk factor for epilepsy is based on several reasons.
Firstly, the p.T1174S variant is overrepresented in epilepsy patients (P = 5.68 x 10−4). Secondly,
it segregates with the disease in our, and, previously analyzed families (Table 2, Fig 1). It was
previously described in patients diagnosed with severe myoclonic epilepsy of infancy (inheri-
tance not determined), Dravet syndrome (inherited from a mother with migraine), myoclonic
astatic epilepsy (inherited from a healthy mother), and repetitively with familial hemiplegic
migraine (FHM) [24, 27]. In our cohort, the p.T1174S mutation was found in patients with
rolandic epilepsy, childhood absence epilepsy, juvenile absence epilepsy, benign familial neonatal
seizures epilepsy and patients with a single generalized tonic-clonic seizure. In the diagnostic
cohort we found patients with unclassified epilepsy with intellectual disability as well as temporal
lobe epilepsy. Additionally, another family with the p.T1174S mutation has been identified (per-
sonal communication with Arvid Suls, University of Antwerp). In this family the mother carries
the variant, as do the six elder siblings of seven. Two of these six carriers are affected by epilepsy
with myoclonic seizures. Finally, previous in vitro electrophysiological recordings of the mutant
p.T1174S Nav1.1 channel support the variant pathogenicity [19]. The molecular analysis revealed
two divergent effects: a positive shift of the activation curve and deceleration of recovery from
fast inactivation–consistent with a loss of function, and an increase of persistent current (I
(NaP))–consistent with a gain of function [19]. On the other hand, the p.T1174S variant was
only predicted to be damaging by one in silico program (FATHMM, Table 3) and was inherited
by unaffected parent in the replication cohort five out of seven times.
Besides the unclear role of the p.T1174S variant, the majority of our investigated SCN1A
HGMD variants cannot be classified as clearly pathogenic. Based on our results, we assume
that a significant fraction of patients diagnosed with pathogenic SCN1Amutations may actu-
ally not carry an SCN1A variant of relevance. The role of SCN1Amissense mutations in the
pathogenesis of common epilepsies may thus be overstated (in general and e. g. studies in
Table 2). Previous conclusions were frequently based on comparisons of allele frequencies
between patients and small control datasets often without molecular follow up of the variant
(Table 2). By accessing large gene mutation databases of non-epileptic individuals (e.g. http://
exac.broadinstitute.org) we show that previous studies have been underpowered. In order to
draw a definitive conclusion about pathogenicity for variants in common epilepsy syndromes,
which are also present in healthy individuals, functional studies are mandatory (e.g. functional
characterization of patient neurons derived form induced pluripotent cells).
The conclusions drawn from our study can be translated to other fields of research. Several
prediction tools [35–39] evaluating the pathogenic potential of DNA sequence alterations are
trained with variant lists extracted from the HGMD. Given that the disease association of the
annotated SCN1A variants have to be questioned, it is likely that a similar picture can be seen
for other complex diseases and genes. Simply extracting HGMD variants as training sets might
bias prediction algorithms and machine learning approaches.
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Overall, we highlight the ambiguities of variant classification in common epilepsy syn-
dromes and emphasize that the majority of SCN1A variants could not be re-classified as patho-
genic. Furthermore, our results warrant careful assessment of variants previously reported in
small cohort studies.
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S1 Fig. SCN1A domain organization and mutations. The schematic diagram showing the
domain organization of the alpha subunit of the voltage-gated sodium ion channel coded by
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